CD103+CD56+ ILCs Are Associated with an Altered CD8+ T-cell Profile within the Tumor Microenvironment.

Area of Science:

• Immunology
• Cancer Biology
• Cell Biology

Background:

• Immunotherapies show promise in cancer treatment but have variable response rates.
• Understanding the tumor microenvironment (TME) is crucial for enhancing antitumor immunity.
• Innate lymphoid cells (ILCs) and natural killer (NK) cells play regulatory roles in immunity.

Purpose of the Study:

• To identify novel immune cell populations within the TME that influence antitumor responses.
• To characterize a distinct ILC subset expressing CD103 and its functional implications.

Main Methods:

• Utilized flow cytometry to identify CD103+CD56+ cells.
• Employed single-cell multiomic and spatial analyses to profile ILCs and associated immune cells.
• Assessed the proliferative capacity of tumor-infiltrating lymphocytes in culture.

Main Results:

• Identified CD103+CD56+ ILCs as a distinct population with unique molecular and transcriptomic profiles.
• These CD103+CD56+ ILCs were associated with reduced CD8+ T cell activity (granzyme B expression).
• CD103+CD56+ ILCs correlated with poor tumor-infiltrating lymphocyte proliferation in vitro.

Conclusions:

• Discovered a novel CD103+CD56+ ILC subset with potentially inhibitory functions in the TME.
• This ILC population is linked to CD8+ T cells exhibiting diminished antitumor activity.
• Further research into these inhibitory ILCs may reveal strategies to enhance cancer immunotherapy efficacy.